We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Successful treatment of non-small cell lung cancer with gefitinib after erlotinib-induced severe eyelid erosion: Two case reports.
- Authors
Nobuhiro Asai; Yoshihiro Ohkuni; Etsuro Yamaguchi; Norihiro Kaneko; Asai, Nobuhiro; Ohkuni, Yoshihiro; Yamaguchi, Etsuro; Kaneko, Norihiro
- Abstract
Gefitinib and erlotinib are first-generation, small, molecular inhibitors of the epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). Even as these drugs have led to a paradigm shift in the treatment of advanced non-small cell lung cancer (NSCLC), drug-induced adverse effects are commonly seen. We experienced two cases of NSCLC patients who developed erlotinib-induced eyelid erosion and were then successfully treated with gefitinib, without recurrence of toxicity or disease progression. As far as we had investigated, this is the first report documenting the successful cases treated with gefitinib after erlotinib-related severe eyelid erosion.
- Subjects
CANCER treatment; NON-small-cell lung carcinoma; GEFITINIB; ERLOTINIB; EYELID diseases; EPIDERMAL growth factor receptors; CANCER invasiveness; THERAPEUTICS
- Publication
Journal of Cancer Research & Therapeutics, 2015, Vol 11, Issue 3, p653
- ISSN
0973-1482
- Publication type
case study
- DOI
10.4103/0973-1482.139392